<DOC>
	<DOCNO>NCT02597439</DOCNO>
	<brief_summary>The purpose study determine whether omega-3 fatty acid effective prevention psychosis individual ultra-high risk psychosis .</brief_summary>
	<brief_title>Placebo-controlled Trial Subjects Ultra-high Risk Psychosis With Omega-3 Fatty Acids Europe</brief_title>
	<detailed_description>PURPOSE randomize double-blind placebo-controlled study . Main objective ass effectivity omega-3 fatty acid treatment prevention psychosis . The primary outcome measure rate transition psychosis determine CAARMS . Subjects age range 13-20 year higher chance develop psychosis , determine CAARMS , treat 6 month omega-3 fatty acid placebo . This study conduct 18 site 9 country .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>Written inform consent subject . For individual young 18 year age parent / legal representative need give consent , subject provide assent ( whether latter require depend local law regulation ) . UHR diagnosis make use Comprehensive Assessment AtRisk Mental States ( CAARMS ) ( Yung et al. , 2005 ) . Subjects meet one follow criterion : ( ) attenuate psychotic symptom , ( b ) brief limited intermittent psychotic symptom ( history one episodes frank psychotic symptom resolve spontaneously within 1 week past year ) , ( c ) either presence schizotypal personality disorder family history psychosis firstdegree relative , three together recent decline function . Any clinically significant medical condition may influence result trial affect ability take part trial . Laboratory screen value consider clinically relevant medical doctor transaminase , thyroid hormone coagulation parameter Current past DSMIV diagnosis psychosis , measure KSADSPL Current treatment antipsychotic moodstabilising agent Intake antipsychotic moodstabilising agent two week prior study inclusion Intake antipsychotic agent equivalent total haloperidol use &gt; 50 mg six month prior study inclusion A firstdegree relative ( i.e . parent , offspring sibling ) participate study UHR diagnosis basis attenuate psychotic symptom entirely explain acute intoxication Current aggression dangerous behaviour ( PANSS G14 score 5 ) Current suicidality / selfharm ( PANSS G6 score 7 ) Current DSMIV diagnosis alcohol substance dependence measure KSADSPL Any current previous neurological disorder , include epilepsy History head injury result unconsciousness last least 1 hour IQ &lt; 70 More 4 week regular omega3 supplementation ( &gt; 2 daily capsule standard strength provide &gt; 600 mg combine EPA/DHA ) within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ultra-high risk</keyword>
	<keyword>UHR</keyword>
	<keyword>psychosis</keyword>
</DOC>